ArticleMolecular biology of the cell2002
Role of adaptor complex AP-3 in targeting wild-type and mutated CD63 to lysosomes.
Article in Molecular biology of the cell, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 91 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
91 citing papers in PubMed, 244 citations in OpenAlex.
- Exploring the immunological effects of antibody-drug conjugates.Nature reviews. Clinical oncology · 2026Review
- EV-SPEC: Decoding the Spatial Proteomic Signature of the Extracellular Vesicle Corona.Journal of extracellular biology · 2026Article
- Nano-Flow Cytometry of Single Extracellular Vesicles Reveals Subpopulation Differences Across Cell Types and Pharmacological Perturbations.Journal of extracellular vesicles · 2026Article
- Bispecific antibody-drug conjugates: a modular blueprint for next-generation cancer therapeutics.Archives of pharmacal research · 2026Review
- Review
- Article
- Tetraspanin proteins in membrane remodeling processes.Journal of cell science · 2024Review
- Tetraspanins: structure, dynamics, and principles of partner-protein recognition.Trends in cell biology · 2024Review
- Bispecific antibody drug conjugates: Making 1+1>2.Acta pharmaceutica Sinica. B · 2024Review
- Optogenetic manipulation of lysosomal physiology and autophagy-dependent clearance of amyloid beta.PLoS biology · 2024Article
- Reduced myeloid commitment and increased uptake by macrophages of stem cell-derived HPS2 neutrophils.Life science alliance · 2024Article
- The HSPB1-p62/SQSTM1 functional complex regulates the unconventional secretion and transcellular spreading of the HD-associated mutant huntingtin protein.Human molecular genetics · 2023Article
- Engineered exosomes for studies in tumor immunology.Immunological reviews · 2022Review
- Homosalate boosts the release of tumour-derived extracellular vesicles with protection against anchorage-loss property.Journal of extracellular vesicles · 2022Article
- Deliver on Time or Pay the Fine: Scheduling in Membrane Trafficking.International journal of molecular sciences · 2021Review
- Specificities of exosome versus small ectosome secretion revealed by live intracellular tracking of CD63 and CD9.Nature communications · 2021Article
- Epstein-Barr Virus LMP1 Modulates the CD63 Interactome.Viruses · 2021Article
- A hybridoma-derived monoclonal antibody with high homology to the aberrant myeloma light chain.PloS one · 2021Article
- Expression of an endosome-excluded Cd63 prevents axis elongation inmicroPublication biology · 2020Article
- A live cell reporter of exosome secretion and uptake reveals pathfinding behavior of migrating cells.Nature communications · 2020Article
31 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
CD63 is a lysosomal membrane protein that belongs to the tetraspanin family. Its carboxyterminal cytoplasmic tail sequence contains the lysosomal targeting motif GYEVM. Strong, tyrosine-dependent interaction of the wild-type carboxyterminal tail of CD63 with the AP-3 adaptor subunit mu 3 was observed using a yeast two-hybrid system. The strength of interaction of mutated tail sequences with mu 3 correlated with the degree of lysosomal localization of similarly mutated human CD63 molecules in stably transfected normal rat kidney cells. Mutated CD63 containing the cytosolic tail sequence GYEVI, which interacted strongly with mu 3 but not at all with mu 2 in the yeast two-hybrid system, localized to lysosomes in transfected normal rat kidney and NIH-3T3 cells. In contrast, it localized to the cell surface in transfected cells of pearl and mocha mice, which have genetic defects in genes encoding subunits of AP-3, but to lysosomes in functionally rescued mocha cells expressing the delta subunit of AP-3. Thus, AP-3 is absolutely required for the delivery of this mutated CD63 to lysosomes. Using this AP-3-dependent mutant of CD63, we have shown that AP-3 functions in membrane traffic from the trans-Golgi network to lysosomes via an intracellular route that appears to bypass early endosomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.